Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

The Effects of Medication and Parkinson’s Disease Severity on Proprioceptively Encoded Memory Guided Reaching
Movement Disorders
P11 - Poster Session 11 (8:00 AM-9:00 AM)
3-016
To examine the effects of medication (on vs. off) and PD severity (mild-to-moderate vs. advanced) on the performance of proprioceptively encoded memory guided reaching movements.
Proprioceptive inputs can be used to encode spatial locations and program movements to memorized locations. Studies suggest that the basal ganglia are involved in this proprioceptive-motor integration. Patients with Parkinson’s disease (PD), characterized by basal ganglia dysfunction, manifest deficits in proprioceptive-motor integration and impairments in memory guided movements. The effects of anti-Parkinsonian medication and PD severity on impairments during proprioceptively encoded memory guided movements remain unclear. Examining the effect of medication and PD severity will clarify the role of dopaminergic circuits during proprioceptively encoded memory guided reaching and the sustained effectiveness of medication as PD progresses.
Participants with mild-to-moderate (15m, 3f; mean age ± SD: 65.4±5.7 years; off motor UPDRS ± SD, 35.1±8.9) and advanced PD (11m, 3f; 66.2±4 years; 51±13.1) were blindfolded and performed a proprioceptively encoded memory guided reaching task while on and off medication (12-hour overnight withdrawal), over two separate days. Participants used proprioceptive inputs to encode targets (the examiner moved the blindfolded participant’s relaxed arm to three sequential locations), and then reached to the memorized targets as accurately as possible. Dependent outcomes included peak velocity and accuracy. All statistical analyses were performed using SAS Proc Mixed.
Medication had no effect on peak velocity and accuracy in the mild-to-moderate PD group. In the advanced PD group, medication significantly reduced error (mean difference, 0.03m; p<0.01).
Our finding that medication improves reaching accuracy of proprioceptively encoded targets in advanced PD supports the role of dopaminergic circuits in processing proprioceptive inputs during memory guided reaching. Further research is required to ascertain the scope of the proprioceptive deficit relative to healthy controls.
Authors/Disclosures

PRESENTER
No disclosure on file
No disclosure on file
No disclosure on file
Gian D. Pal, MD (Rutgers University) Dr. Pal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Guidepoint. Dr. Pal has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Kyowa Kirin. Dr. Pal has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for CLRM Law. Dr. Pal has stock in Baudax Bio. The institution of Dr. Pal has received research support from National Institutes of Health. The institution of Dr. Pal has received research support from Parkinson's Foundation. Dr. Pal has received personal compensation in the range of $500-$4,999 for serving as a Consultant with RKV Firm.
Leonard Verhagen Metman, MD, PhD (Northwestern University) Dr. Verhagen Metman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AbbVie. Dr. Verhagen Metman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Abbott. Dr. Verhagen Metman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Mitsubishi Tanabe. Dr. Verhagen Metman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Supernus. Dr. Verhagen Metman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AbbVie. Dr. Verhagen Metman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cerevel. Dr. Verhagen Metman has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Frontiers.
No disclosure on file
Daniel Corcos, PhD (Northwestern University) Daniel Corcos, PhD has nothing to disclose.
No disclosure on file